s-ketamine related neurometabolic molecular pathway
Conditions
Interventions
experiment group:Sufentanil 2 µg/kg + ketochromate tromethamine 90 mg + S-ketamine 50 mg + tropisetron 30 mg + 0.9% sodium chloride solution, the volume is 120 ml
control group:Sufentanil 2 µg/kg +ketochromate tromethamine 90 mg +tropisetron 30 mg + 0.9% sodium chloride solution, the volume is 120 ml
Sponsors
Peking University Cancer Hospital & Institute
Eligibility
Sex/Gender
Female
Age
45 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 45 to 65 years, 45 inclusive; 2. BMI: 18-30 kg/m^2; 3. ASA grade II-III; 4. Main viscera tissues including liver, kidney, heart, brain and lung show no remarkable histopathological abnormalities or lesions; 5. Patients with an expected hospital stay of 4 days or more for elective tumor surgery; 6. Surgery can be completed before 20:00.
Exclusion criteria
Exclusion criteria: 1. Refused to participate in this study; 2. Patients with tumor recurrence; 3. Combined with primary malignant tumors in other parts; 4. Received multiple operations during a single surgical operation; 5. Received long-term psychotropic drug treatment, hormone therapy, and long-term use of opioids or non-steroidal antibiotics. 6. Patients with inflammatory analgesics, preoperatively diagnosed as schizophrenia, dementia, Alzheimers disease, delirium; 7. Unable to communicate due to language impairment or end-stage disease; 8. Long-term use of Soporifics; 9. History of obstructive sleep apnea syndrome; 10.Failure to control or untreated hypertensive patients (arterial hypertension, resting systolic/diastolic blood pressure exceeding 180/100 mmHg); 11.Severe heart block and/or severe ventricular insufficiency; 12.Severe liver dysfunction (Child -Pugh C); 13.Severe renal dysfunction (receiving renal replacement therapy before surgery); 14.Allergic to s-ketamine or sufentanil active ingredients or excipients; 15.Other conditions deemed unsuitable for inclusion by the investigator (reason to be specified).
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Dizziness after surgery;Postoperative nausea;other adverse reaction; | — |
Primary
| Measure | Time frame |
|---|---|
| Serum proteomics; | — |
Countries
China
Contacts
Public ContactTan Hongyu
Peking University Cancer Hospital & Institute
Outcome results
None listed